Miriam Mwachinga: Let’s Focus More on Rare Diseases and Their Impact on Quality of Life
Miriam Mwachinga, General Practitioner, Internal Medicine, Medical Affairs at Healthcare Industry, Pharmaceutical Ind, shared on LinkedIn:
”One of my college professors once made a comment that has stayed with me over the years.
Diseases that affect 1 in a million often seem insignificant, but the impact on your quality of life if you are that 1 person in a million is huge.
Rare diseases tend to be overlooked because the cost: benefit ratio doesn’t make economic sense when it comes to drug development, but that doesn’t make them any less significant.
Hemophilia A is the most common genetic X-linked disease, but still far behind when it comes to clinical research.
With Rare Disease Day coming up later this month, let’s all focus a bit more on rare diseases.”

Stay updated with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026